AstraZeneca | Results Presentation Deck | 42 slides

AstraZeneca · 2021-07
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

42
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detailBeat · Attention
02
other
Open slide detailBeat · Attention
03
front_matter
Open slide detailBeat · Attention
04
front_matter
Open slide detailBeat · Attention
05
Includes footnotes explaining abbreviations and specific financial exclusions.summarize
Open slide detailBeat · Attention
06
The slide uses a table to categorize pipeline progress into regulatory approvals, submissions, and phase III data readouts.summarize
Open slide detailBeat · NeedLoop · Pattern Hunter
07
The slide uses a combination of a bar chart for historical growth trends and a waterfall-style bar chart for new medicine revenue contribution.analyze_data
Open slide detailBeat · NeedLoop · Pattern Hunter
08
The slide presents two distinct tables side-by-side, comparing performance by therapeutic area and by geography.analyze_data
Open slide detailBeat · NeedLoop · Pattern Hunter
09
The slide uses a Venn-like circular layout to connect the two companies with the acquisition details.establish_context
Open slide detailBeat · NeedLoop · Pattern Hunter
10
front_matter
Open slide detailBeat · NeedLoop · Pattern Hunter
11
The slide uses a consistent color-coding scheme for regions (US, Europe, ERoW, EM) across both products.analyze_data
Open slide detailBeat · SatisfactionLoop · Pattern Hunter
12
Slide includes two charts: a stacked bar chart for sales growth and a stacked bar chart for collaboration revenue.analyze_data
Open slide detailBeat · SatisfactionLoop · Pattern Hunter
13
Includes footnotes detailing specific market segments (CLL, MCL, mBC, mGC) and data sources.analyze_data
Open slide detailBeat · SatisfactionLoop · Pattern Hunter
14
The slide uses a background image of a human torso with cellular/molecular overlays, typical of pharmaceutical corporate presentations.summarize
Open slide detailBeat · SatisfactionLoop · Pattern Hunter
15
The slide uses stacked bar charts to show revenue composition over time from Q1 2018 to Q2 2021.analyze_data
Open slide detailBeat · Satisfaction
16
Includes product imagery and regional breakdown of revenue performance.analyze_data
Open slide detailBeat · Satisfaction
17
Includes market share charts and regional revenue highlights for specific drug launches.analyze_data
Open slide detailBeat · Satisfaction
18
The chart shows a stacked bar chart of revenue over time, split by China and EM excluding China.analyze_data
Open slide detailBeat · Satisfaction
19
Includes a table of revenue by product and a list of reporting milestones.analyze_data
Open slide detailBeat · Satisfaction
20
front_matter
Open slide detailBeat · Satisfaction
21
The table uses CER (Constant Exchange Rates) for percentage changes. Footnotes clarify definitions of R&D, SG&A, and percentage points.analyze_data
Open slide detailBeat · Action
22
Includes a footnote regarding exchange rates and gross margin calculation methodology.analyze_data
Open slide detailBeat · Action
23
The slide uses a stacked bar chart for profit mix and a waterfall chart for net debt bridge.analyze_data
Open slide detailBeat · Action
24
The central image depicts a laboratory setting, reinforcing the healthcare/pharma context.analyze_data
Open slide detailBeat · Action
25
The slide provides high-level financial guidance updates.summarize
Open slide detailBeat · Action
26
front_matter
Open slide detailBeat · Action
27
Slide 27 of a presentation, likely from AstraZeneca.summarize
Open slide detailBeat · Action
28
The slide uses Kaplan-Meier survival curves to demonstrate efficacy in two major Phase III trials.summarize
Open slide detailBeat · ActionLoop · Cost Of Inaction
29
The slide uses a three-column layout to summarize clinical efficacy, market need, and future pipeline milestones.summarize
Open slide detailBeat · ActionLoop · Cost Of Inaction
30
The slide uses a two-column layout to contrast early-stage development with late-stage/marketed assets.present_solution
Open slide detailBeat · ActionLoop · Cost Of Inaction
31
Includes a Kaplan-Meier survival curve for the OlympiaA trial.summarize
Open slide detailBeat · ActionLoop · Cost Of Inaction
32
Includes pre/post treatment MRI images for Koselugo.illustrate_case
Open slide detailBeat · ActionLoop · Cost Of Inaction
33
The slide uses a two-column layout to contrast early-stage pipeline assets (left) with late-stage/lifecycle management assets (right).present_solution
Open slide detailBeat · ActionLoop · Cost Of Inaction
34
The slide uses a matrix-style layout to organize events by time period and event type.plan_implementation
Open slide detailBeat · ActionLoop · Cost Of Inaction
35
front_matter
Open slide detailBeat · Action
36
The slide uses a three-column layout to summarize key business pillars.summarize
Open slide detailBeat · Action
37
state_next_steps
Open slide detailBeat · Action
38
Status as of 29 July 2021.appendix
39
Includes a visual representation of market expansion for gMG.appendix
40
The slide uses a grid-based layout to contrast early-stage pipeline assets with late-stage and existing lifecycle management assets.appendix
41
Includes a group photo and a contact list.introduce_nominees